Arcus Biosciences, INC. (RCUS) — 10-Q Filings

10-Q Filings (6)

• Arcus Biosciences' Losses Widen Amid Increased R&D Spend — Oct 28, 2025 Risk: high
  Arcus Biosciences, Inc. (RCUS) reported a net loss of $135 million for the three months ended September 30, 2025, a significant increase from the $92 million ne
• Arcus Biosciences Revenue Soars 105% on Collaboration Boost — Aug 6, 2025 Risk: medium
  Arcus Biosciences reported a significant increase in total revenue for the three and six months ended June 30, 2025, primarily driven by collaboration agreement
• Arcus Biosciences Q1 2025 Update — May 6, 2025 Risk: medium
  Arcus Biosciences, Inc. reported its first quarter 2025 results, ending March 31, 2025. The company's revenue streams include License and Development Services R
• Arcus Biosciences Q3 2024 10-Q Filed — Nov 6, 2024 Risk: medium
  Arcus Biosciences, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported License and Development Services Revenue for the third qua
• Arcus Biosciences Q2 Revenue Surges on Licensing Deals — Aug 8, 2024 Risk: medium
  Arcus Biosciences, Inc. reported its Q2 2024 results, with total revenue for the three months ended June 30, 2024, reaching $40.8 million, a significant increas
• Arcus Biosciences, Inc. Files 10-Q for Period Ending March 31, 2024 — May 8, 2024 Risk: medium
  Arcus Biosciences, Inc. (RCUS) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Arcus Biosciences reported License and Development Services Revenue

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX